Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, costs, and how each impacts quality of life.

Learn how to self-administer SCIg at home for primary immunodeficiency. Tips on preparation, reducing pain, managing ...

The US Food and Drug Administration said Monday it had issued an emergency use authorization for Eli Lilly and Co's monoclonal antibody therapy to treat mild to moderate coronavirus infections in ...

On the same day North Carolina hospitals reported a record number of COVID-19 patients in intensive care units across the state, Gov. Roy Cooper signaled he will take action expanding access to a ...

While doctors have stressed the importance of COVID-19 vaccinations, there are also coronavirus treatments helping sick patients stay out of the hospital. Monoclonal antibody therapy is gaining ...

We included 692 patients, of whom 6.7% (n = 47) had experienced one or more IRRs (n = 63). The highest incidence of IRRs (n = 50) were found in patients treated with rituximab (incidence IRR 26%), ...

Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or ...

From 31 centers, 166 patients were entered. Of this intent-to-treat group, 48% responded. With a median follow-up duration of 11.8 months, the projected median time to progression for responders is 13 ...

If you’re older than 12 and test positive for COVID-19, you most likely qualify to receive monoclonal antibody treatment on Texas’ dime. For most, the largest barrier to getting the early-stage ...

Advances in cancer immunotherapy have yielded chimeric antigen receptor (CAR) T-cell and bispecific antibody (BsAb) treatments, which redirect T cells to tumor cells regardless of their T-cell ...